SGLT2 Inhibitor Role for Isolated Kidney Disease

Empagliflozin significantly cut progression of chronic kidney disease in a pivotal trial that included people without diabetes or heart failure.
Medscape Medical News

source https://www.medscape.com/viewarticle/983521?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?